Theralase Technologies Inc
XTSX:TLT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.14
0.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Theralase Technologies Inc
Theralase Technologies Inc
Total Equity
Theralase Technologies Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Total Equity
CA$1.7m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Titan Medical Inc
TSX:TMD
|
Total Equity
$2.7m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-21%
|
|
|
Profound Medical Corp
TSX:PRN
|
Total Equity
$39.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Opsens Inc
TSX:OPS
|
Total Equity
CA$33.8m
|
CAGR 3-Years
30%
|
CAGR 5-Years
13%
|
CAGR 10-Years
26%
|
|
|
Nanalysis Scientific Corp
XTSX:NSCI
|
Total Equity
CA$23.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
MedMira Inc
XTSX:MIR
|
Total Equity
-CA$16.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-10%
|
|
Theralase Technologies Inc
Glance View
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.
See Also
What is Theralase Technologies Inc's Total Equity?
Total Equity
1.7m
CAD
Based on the financial report for Jun 30, 2024, Theralase Technologies Inc's Total Equity amounts to 1.7m CAD.
What is Theralase Technologies Inc's Total Equity growth rate?
Total Equity CAGR 10Y
-8%
Over the last year, the Total Equity growth was -19%. The average annual Total Equity growth rates for Theralase Technologies Inc have been -39% over the past three years , -8% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet
